The cluster is driven entirely by mega-passive institutions adding during a price decline, suggesting confidence in long-term fundamentals. Traders should monitor for stabilization in revenue trends and potential re-rating if genetic testing demand improves.
How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 2 $5.01entry
- T+1 · 9mo ago +5.59%α +6.50% · $5.29
- T+5 · 8mo ago −3.99%α −2.78% · $4.81
- T+20 · 8mo ago −12.97%α −5.04% · $4.36
- T+60 · 6mo ago −23.15%α −32.48% · $3.85
How similar events traded
Executive Summary
Three major passive institutions, Morgan Stanley, Wells Fargo, and UBS, significantly increased their positions in Myriad Genetics (MYGN) during Q4 2024, with UBS doubling its stake. Despite a decline in the dollar value of holdings due to falling stock price, the aggregate buying represents a strong signal of institutional accumulation.
Key Financial Metrics
Institutional Positions
Net institutional flow: -$6.1M
▲ Buyers (3)
| Institution | Action | Change | Position Value | Value Δ |
|---|---|---|---|---|
| Morgan Stanley | ADD | +45.9% | $17.6M | -$6.5M |
| Wells Fargo | ADD | +69.3% | $2.9M | -$528.3K |
| UBS | DOUBLED | +134.2% | $6.5M | $961.0K |
Key Facts
- Morgan Stanley increased shares by 45.9% (404.1K shares added), now holding 1.29M shares valued at $17.6M
- Wells Fargo increased shares by 69.3% (87.7K shares added), now holding 214.1K shares valued at $2.9M
- UBS doubled its position with a 134.2% increase (273.6K shares added), now holding 477.6K shares valued at $6.5M
- No institutional selling was reported in this quarter
- Aggregate net buying: $27.1M in current holdings with a net dollar change of -$6.08M, indicating share increases amid price decline
Financial Impact
Institutions added 765.4K shares during the quarter, increasing holdings by an aggregate of $27.1M in current value despite a $6.08M net decrease in value due to falling share price, signaling accumulation during weakness
Risk Factors
- All buyers are passive managers, which may reflect index weighting changes rather than active conviction
- The declining market value despite share increases indicates meaningful stock price pressure during the quarter
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 institutional 13F filing from SEC EDGAR.
| Document | Accession Number |
|---|---|
| INST-CLUSTER Data (Synthetic) | inst-cluster-MYGN-2024-Q4 |
Track record
16 reports on MYGN
2 of 3 bullish or bearish reports moved the stock their way by T+1. Best: +13.54% at T+5 after the Oct 20, 2026 report. 2 of 3 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $5.57 settles Nov 18
- Nov 9, 20267d ago 8-K Neutral 2/10 Entry $5.67 to $5.72 ▲ +0.88% −0.44% vs SPY
- Nov 5, 202611d ago 8-K Neutral 4/10 Entry $6.29 to $5.92 ▼ −5.88% −6.19% vs SPY
- Nov 4, 202612d ago 8-K Mixed 6/10 Entry $6.29 to $5.92 ▼ −5.88% −6.19% vs SPY
- Nov 4, 202612d ago Institutional Cluster Neutral 2/10 Entry $6.02 to $6.29 ▲ +4.49% +8.89% vs SPY
- Oct 27, 202620d ago SC 13G/A Neutral 2/10 Entry $6.63 to $6.67 ▲ +0.60% +0.99% vs SPY
- Oct 20, 202627d ago 8-K Bullish 7/10 Entry $5.54 to $5.57 ▲ +0.54% +0.02% vs SPY
- Oct 15, 20264w ago Press Release Neutral 1/10 Entry $3.98 No price data
- Oct 9, 20265w ago 8-K Neutral 3/10 Entry $4.20 to $4.08 ▼ −2.86% −2.85% vs SPY
- Sep 16, 20268w ago 8-K Neutral 3/10 Entry $3.86 to $4.14 ▲ +7.25% +6.12% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers